Etiopathogenetic aspects of central (hypogonadotropic) hypogonadism in female
https://doi.org/10.21886/2219-8075-2019-10-4-15-27
Abstract
Central hypogonadism (CH) is a rare endocrine disorder caused by the disfunction of production, secretion and/or biological action of gonadotropin-releasing hormone (GnRH), which is the main hormonal regulator of hypothalamo-pituitarygonadal axis in human. Female CH is important medical and social concern due to large amount of infertile couples. Etiological structure of this condition is heterogeneous and diff ers between congenital and acquired forms. Congenital forms have a genetic predisposition: currently about 50 genes associated with CH have been found. However, genetic basis can be identifi ed just in half of CH cases. Speaking about acquired forms of CH, important to pay attention on hypothalamo-pituitary area condition. In case of intact state the functional form of CH can be diagnosed, the presence of structural disorders in this area speaks in favor of the organic cause of CH. In this review are summarized current knowledge in the fi eld of etiology and pathogenesis of female central hypogonadism.
About the Authors
A. S. Loktionova
MF Vladimirsky Moscow Regional Scientifi c Research Clinical Institute
Russian Federation
Russian Federation
assistant of Particular endocrinology course, Department of Endocrinology,
Moscow
I. A. Ilovayskaya
MF Vladimirsky Moscow Regional Scientifi c Research Clinical Institute
Russian Federation
Russian Federation
Cand. Sci. (Med.), heading researcher of the Th erapeutic Endocrinology Department, Associate Professor of Particular endocrinology course, Endocrinology Department,
Moscow
References
1. Nazarenko TA. Stimulation of ovarian function. Moscow. MEDpress-inform; 2008 (In Russ).
2. Norton W. Fertility. In: Nursing Management of Women’s Health; 2019. p. 103–25. DOI:10.1007/978-3-030-16115-6_6
3. Stamatiades GA, Kaiser UB. Gonadotropin regulation by pulsatile GnRH: signaling and gene expression. Mol Cell Endocrinol. 2018;463:131–41. DOI: 10.1016/j.mce.2017.10.015
4. Pettersson F, Fries H, Nillius SJ. Epidemiology of secondary amenorrhea: I. Incidence and prevalence rates. Am J Obstet Gynecol. 1973;117(1):80–6. DOI:10.1016/s0002-9378(16)33686-9
5. Meczekalski B, Katulski K, Czyzyk A, Podfi gurna-Stopa A, Maciejewska-Jeske M. Functional hypothalamic amenorrhea and its infl uence on women’s health. J Endocrinol Invest. 2014;37(11):1049–56. DOI:10.1007/s40618-014-0169-3
6. Chernukha GE, Gusev DV, Tabeeva GI, Prilutskaia VY. Pathophysiological features of development of functional hypothalamic amenorrhea in patients with anorexia nervosa. Gynecology. 2018;20(1). (In Russ) DOI:10.26442/2079-5696_20.1.16-22
7. Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril. 2006;86(5):S148–55. DOI: 10.1016/j.fertnstert.2006.08.013
8. Ilovayskaya IA, Zektser VYu, Mikhaylova DS, Donina EYu, Goncharov NP, Mel’nichenko GA. The functional state of the hypothalamic-hypophyseal-ovarian system in central hypogonadism in women. Voprosy ginekologii akusherstva I perinatologii. 2008;7(5):22–8. (In Russ).
9. Seminara SB, Hayes FJ, Crowley Jr WF. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann’s syndrome): pathophysiological and genetic considerations. Endocr Rev. 1998;19(5):521–39. DOI:10.1210/edrv.19.5.0344
10. Boehm U, Bouloux PM, Dattani MT, De Roux N, Dodé C, Dunkel L, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11(9):547–64. DOI: 10.1038/nrendo.2015.112
11. Wray S, Grant P, Gainer H. Evidence that cells expressing luteinizing hormone-releasing hormone mRNA in the mouse are derived from progenitor cells in the olfactory placode. Proc Natl Acad Sci. 1989;86(20):8132–6. DOI:10.1073/pnas.86.20.8132
12. Shin S-J, Sul Y, Kim JH, Cho JH, Kim G-H, Kim JH, et al. Clinical, endocrinological, and molecular characterization of Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism: a single center experience. Ann Pediatr Endocrinol Metab. 2015;20(1):27. DOI: 10.6065/apem.2015.20.1.27
13. Stamou MI, Georgopoulos NA. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. Metabolism. 2018;86:124–34. DOI: 10.1016/j.metabol.2017.10.012
14. Dye AM, Nelson GB, Diaz-Th omas A. Delayed puberty. Pediatr Ann. 2018;47(1):e16–22. DOI: 10.3928/19382359-20171215-01
15. Stamou MI, Cox KH, Crowley Jr WF. Discovering genes essential to the hypothalamic regulation of human reproduction using a human disease model: adjusting to life in the “-omics” era. Endocr Rev. 2015;2016(1):4–22. DOI: 10.1210/er.2015-1045
16. Topaloğlu AK. Update on the Genetics of Idiopathic Hypogonadotropic Hypogonadism. J Clin Res Pediatr Endocrinol. 2017;9(Suppl 2):113–22. DOI: 10.4274/jcrpe.2017.s010
17. Cassatella D, Howard SR, Acierno JS, Xu C, Papadakis GE, Santoni FA, et al. Congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty have distinct genetic architectures. Eur J Endocrinol. 2018;178(4):377– 88. DOI: 10.1530/eje-17-0568
18. Eneva NG, Nefedova LN, Loktionova AS, Khusniyarova KA, Ilovaiskaya IA, Kim AI. On the problem of female infertility: a search for genetic markers. Biology Bulletin Reviews. (In Russ) 2018;8(3):256–65. DOI: 10.1134/s2079086418030040
19. Franco B, Guioli S, Pragliola A, Incerti B, Bardoni B, Tonlorenzi R, et al. A gene deleted in Kallmann’s syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature. 1991;353(6344):529. DOI: 10.1038/353529a0
20. Sykiotis GP, Plummer L, Hughes VA, Au M, Durrani S, Nayak-Young S, et al. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci U S A. 2010;107(34):15140–4. DOI: 10.1073/pnas.1009622107
21. Hardelin J, Julliard AK, Moniot B, Soussi‐Yanicostas N, Verney C, Schwanzel‐Fukuda M, et al. Anosmin‐1 is a regionally restricted component of basement membranes and interstitial matrices during organogenesis: implications for the developmental anomalies of X chromosome‐ linked Kallmann syndrome. Dev Dyn an Off Publ Am Assoc Anat. 1999;215(1):26–44. DOI: 10.1002/(sici)1097-0177(199905)215:13.3.co;2-4
22. Pitteloud N, Meysing A, Quinton R, Acierno Jr JS, Dwyer AA, Plummer L, et al. Mutations in fi broblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol Cell Endocrinol. 2006;254:60–9. DOI: 10.1016/j.mce.2006.04.021
23. Falardeau J, Chung WCJ, Beenken A, Raivio T, Plummer L, Sidis Y, et al. Decreased FGF8 signaling causes defi ciency of gonadotropin-releasing hormone in humans and mice. J Clin Invest. 2008;118(8):2822–31. DOI: 10.1172/jci34538
24. Miraoui H, Dwyer AA, Sykiotis GP, Plummer L, Chung W, Feng B, et al. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identifi ed in individuals with congenital hypogonadotropic hypogonadism. Am J Hum Genet. 2013;92(5):725–43. DOI: 10.1016/j.ajhg.2013.04.008
25. Prosser HM, Bradley A, Caldwell MA. Olfactory bulb hypoplasia in Prokr2 null mice stems from defective neuronal progenitor migration and diff erentiation. Eur J Neurosci. 2007;26(12):3339–44. DOI: 10.1111/j.1460-9568.2007.05958.x
26. Cerrato F, Shagoury J, Kralickova M, Dwyer A, Falardeau J, Ozata M, et al. Coding sequence analysis of GNRHR and GPR54 in patients with congenital and adult-onset forms of hypogonadotropic hypogonadism. Eur J Endocrinol. 2006;155(suppl_1):S3–10. DOI: 10.1530/eje.1.02235
27. Chan Y-M, de Guillebon A, Lang-Muritano M, Plummer L, Cerrato F, Tsiaras S, et al. GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci. 2009;106(28):11703–8. DOI: 10.1073/pnas.0903449106
28. Seminara SB, Messager S, Chatzidaki EE, Th resher RR, Acierno Jr JS, Shagoury JK, et al. Th e GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614–27. DOI: 10.1056/nejmoa035322
29. de Roux N, Genin E, Carel J-C, Matsuda F, Chaussain J-L, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci. 2003;100(19):10972–6. DOI: 10.1073/pnas.1834399100
30. Topaloglu AK, Tello JA, Kotan LD, Ozbek MN, Yilmaz MB, Erdogan S, et al. Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med. 2012;366(7):629– 35. DOI: 10.1097/ogx.0b013e31825bc1be
31. Murphy KG. Kisspeptins: regulators of metastasis and the hypothalamic‐pituitary‐gonadal axis. J Neuroendocrinol. 2005;17(8):519–25. DOI: 10.1111/j.1365-2826.2005.01328.x
32. Navarro VM, Gottsch ML, Chavkin C, Okamura H, Clifton DK, Steiner RA. Regulation of gonadotropin-releasing hormone secretion by kisspeptin/dynorphin/neurokinin B neurons in the arcuate nucleus of the mouse. J Neurosci. 2009;29(38):11859–66. DOI: 10.1523/jneurosci.1569-09.2009
33. George JT, Veldhuis JD, Tena‐Sempere M, Millar RP, Anderson RA. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin‐10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol (Oxf). 2013;79(1):100–4. DOI: 10.1111/cen.12103
34. Cortés ME, Carrera B, Rioseco H, del Río JP, Vigil P. Th e role of kisspeptin in the onset of puberty and in the ovulatory mechanism: a mini-review. J Pediatr Adolesc Gynecol. 2015;28(5):286–91. DOI: 10.1016/j.jpag.2014.09.017
35. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet. 1998;18(3):213. DOI: 10.1038/ng0398-213
36. Cravo RM, Margatho LO, Osborne-Lawrence S, Donato Jr J, Atkin S, Bookout AL, et al. Characterization of Kiss1 neurons using transgenic mouse models. Neuroscience. 2011;173:37– 56. DOI: 10.1016/j.neuroscience.2010.11.022
37. Donato Jr J, Cravo RM, Frazão R, Elias CF. Hypothalamic sites of leptin action linking metabolism and reproduction. Neuroendocrinology. 2011;93(1):9–18. DOI: 10.1159/000322472
38. Perry JRB, Day F, Elks CE, Sulem P, Th ompson DJ, Ferreira T, et al. Parent-of-origin-specifi c allelic associations among 106 genomic loci for age at menarche. Nature. 2014;514(7520):92. DOI: 10.1038/nature13545
39. Perry JRB, Corre T, Esko T, Chasman DI, Fischer K, Franceschini N, et al. A genome-wide association study of early menopause and the combined impact of identifi ed variants. Hum Mol Genet. 2013;22(7):1465–72. DOI: 10.1093/hmg/dds551
40. Caronia LM, Martin C, Welt CK, Sykiotis GP, Quinton R, Th ambundit A, et al. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med. 2011;364(3):215–25. DOI: 10.1056/nejmoa0911064
41. Zhu J, Choa RE-Y, Guo MH, Plummer L, Buck C, Palmert MR, et al. A shared genetic basis for self-limited delayed puberty and idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2015;100(4):E646–54. DOI: 10.1210/jc.2015-1080
42. Dwyer AA, Hayes FJ, Plummer L, Pitteloud N, Crowley Jr WF. Th e long-term clinical follow-up and natural history of men with adult-onset idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2010;95(9):4235–43. DOI: 10.1016/s0022-5347(11)60183-3
43. Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M, et al. Functional hypothalamic amenorrhea: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(5):1413–39. DOI: 10.1210/jc.2017-00131
44. Gordon CM. Functional hypothalamic amenorrhea. N Engl J Med. 2010;363(4):365–71. DOI: 10.1056/nejmcp0912024
45. Sidhoum VF, Chan YM, Lippincott MF, Balasubramanian R, Quinton R, Plummer L, et al. Reversal and relapse of hypogonadotropic hypogonadism: Resilience and fragility of the reproductive neuroendocrine system. J Clin Endocrinol Metab. 2014;99(3):861–70. DOI: 10.1210/jc.2013-2809
46. Dwyer AA, Raivio T, Pitteloud N. Management of endocrine disease: reversible hypogonadotropic hypogonadism. Eur J Endocrinol. 2016;174(6):R267–74. DOI: 10.1530/eje-15-1033
47. Meczekalski B, Genazzani AR, Genazzani AD, Warenik-Szymankiewicz A, Luisi M. Clinical evaluation of patients with weight loss-related amenorrhea: neuropeptide Y and luteinizing hormone pulsatility. Gynecol Endocrinol. 2006;22(5):239– 43. DOI: 10.1080/14767050600761992
48. Tolle V, Kadem M, Bluet-Pajot M-T, Frere D, Foulon C, Bossu C, et al. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab. 2003;88(1):109–16. DOI: 10.1210/jc.2002-020645
49. Rivier C, Brownstein M, Spiess J, Rivier J, Vale W. In vivo corticotropin-releasing factor-induced secretion of adrenocorticotropin, β-endorphin, and corticosterone. Endocrinology. 1982;110(1):272–8. DOI: 10.1210/endo-110-1-272
50. Remorgida V, Venturini PL, Anserini P, Salerno E, De LC. Naltrexone in functional hypothalamic amenorrhea and in the normal luteal phase. Obstet Gynecol. 1990;76(6):1115– 20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2122343. Accessed on November 4, 2019.
51. Genazzani AD, Luisi M, Malavasi B, Strucchi C, Luisi S, Casarosa E, et al. Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects. Eur J Endocrinol. 2002;146(3):347–56. DOI: 10.1530/eje.0.1460347
52. Michopoulos V, Mancini F, Loucks TL, Berga SL. Neuroendocrine recovery initiated by cognitive behavioral therapy in women with functional hypothalamic amenorrhea: a randomized, controlled trial. Fertil Steril. 2013;99(7):2084–91. DOI: 10.3410/f.717995501.793475957
53. Ilovayskaya IA. Tumoral and non tumoral pituitary lesions and reproductive system. Acta Biomed Sci. 2012;(3–1). (In Russ.) Available from: https://www.actabiomedica.ru/jour/article/view/871. Accessed on November 4, 2019.
54. Warren MP, Vu C. Central causes of hypogonadism- -functional and organic. Endocrinol Metab Clin North Am. 2003;32(3):593–612. DOI: 10.1016/s0889-8529(03)00042-2
55. Unuane D, Tournaye H, Velkeniers B, Poppe K. Endocrine disorders & female infertility. Best Pract Res Clin Endocrinol Metab. 2011;25(6):861–73. DOI: 10.1016/j.beem.2011.08.001
56. Bergh T, Skarin G, Nillius SJ, Wide L. Pulsatile GnRH therapy–an alternative successful therapy for induction of ovulation in infertile normo-and hyperprolactinaemic amenorrhoeic women with pituitary tumours. Eur J Endocrinol. 1985;110(4):440–4. DOI: 10.1530/acta.0.1100440
57. Kaltsas GA, Mukherjee JJ, Jenkins PJ, Satta MA, Islam N, Monson JP, et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab. 1999;84(8):2731–5. DOI: 10.1210/jcem.84.8.5858
58. Newell-Price J, Grossman AB. Differential diagnosis of Cushing’s syndrome. Arq Bras EndocrinolMetabol. 2007;51(8):1199– 206. DOI: 10.1590/s0004-27302007000800005
59. Ferreira L, Silveira G, Latronico AC. Approach to the patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2013;98(5):1781–8. DOI: 10.1210/jc.2012-3550
60. Faje A. Hypophysitis: evaluation and management. Clin diabetes Endocrinol. 2016;2(1):15. DOI: 10.1186/s40842-016-0034-8
Review
For citations:
Loktionova A.S., Ilovayskaya I.A. Etiopathogenetic aspects of central (hypogonadotropic) hypogonadism in female. Medical Herald of the South of Russia. 2019;10(4):15-27. (In Russ.) https://doi.org/10.21886/2219-8075-2019-10-4-15-27
Views:
3365
Email this article 